Top

Published in:

01-02-2021 | Gout | Original Paper

Trends in the prevalence of kidney stones in the United States from 2007 to 2016

Authors: Api Chewcharat, Gary Curhan

Published in: Urolithiasis | Issue 1/2021

Abstract

The overall prevalence of kidney stones (KS) in the US rose from 3.2% in 1980 to 10.1% in 2016, but the trends in important subgroups have not been reported. We examined the prevalence trends of KS in subgroups of age, sex and race in the US and identified relevant laboratory factors associated with a history of KS using National Health and Nutrition Examination Survey (NHANES) data. We conducted a cross-sectional study among 28,209 US adults aged ≥ 20 years old in the NHANES from 2007 to 2016. We calculated the prevalence of a self-reported history of KS by using weights and standardized to the 2010 US Census population. We also compared relevant laboratory values according to the history of KS. The prevalence of KS decreased from 8.7% in 2007–2008 to 7.2% in 2011–2012 but then increased to 9.0% in 2013–2014 and 10.1% in 2015–2016. However, the overall prevalence of KS increased over 2007–2016 (p-trend = 0.02). Prevalence of KS among men was higher than women. Among men aged 20–79, there were significant quadratic trends in the prevalence of KS. Whereas, the prevalence of KS increased as a linear trend among women aged 20–59 years over 2007–2016. There were no consistent trends in the prevalence of KS by race. The prevalence trend of KS among non-Hispanic whites was 9.8% from 2007 to 2010 then dropped to 7.9% in 2011–2012 and increased to 10.6% in 2013–2014 and 12.1% in 2015–2016. A similar trend was also observed among non-Hispanic blacks. Among Hispanic, the prevalence of KS was 7.6% in 2007–2008 and 7.4% in 2009–2010 and then fluctuated over the next several time periods. For non-Hispanic Asians, the range was 4.4–4.6%. Regarding relevant laboratory factors, after adjusting for sex, race, age, BMI, smoking status, alcohol drinking, history of diabetes and gout, urine albumin-creatinine ratio and serum osmolality were independently associated with the history of KS in women and men. In conclusion, there was substantial variability in KS prevalence across individual 2-year time periods. This variation of period-specific prevalence values emphasizes the importance of looking at long-term trends and using more than a single 2-year cycle in analyses to increase the precision of the estimate. However, there was an overall increase in the prevalence of KS over 2007-2016.

Available only for authorised users

Hyams ES, Matlaga BR (2014) Economic impact of urinary stones. Transl Androl Urol 3(3):278–283. https://doi.org/10.3978/j.issn.2223-4683.2014.07.02CrossRefPubMedPubMedCentral

Rule AD, Krambeck AE, Lieske JC (2011) Chronic kidney disease in kidney stone formers. Clin J Am Soc Nephrol 6(8):2069–2075. https://doi.org/10.2215/CJN.10651110CrossRefPubMedPubMedCentral

Li C-C, Chien T-M, Wu W-J, Huang C-N, Chou Y-H (2018) Uric acid stones increase the risk of chronic kidney disease. Urolithiasis 46(6):543–547. https://doi.org/10.1007/s00240-018-1050-1CrossRefPubMed

Alexander RT, Hemmelgarn BR, Wiebe N, Bello A, Morgan C, Samuel S, Klarenbach SW, Curhan GC, Tonelli M (2012) Kidney stones and kidney function loss: a cohort study. BMJ (Clin Res Ed) 345:e5287. https://doi.org/10.1136/bmj.e5287CrossRef

El-Zoghby ZM, Lieske JC, Foley RN, Bergstralh EJ, Li X, Melton LJ 3rd, Krambeck AE, Rule AD (2012) Urolithiasis and the risk of ESRD. Clin J Am Soc Nephrol 7(9):1409–1415. https://doi.org/10.2215/CJN.03210312CrossRefPubMedPubMedCentral

Taylor EN, Feskanich D, Paik JM, Curhan GC (2016) Nephrolithiasis and risk of incident bone fracture. J Urol 195(5):1482–1486. https://doi.org/10.1016/j.juro.2015.12.069CrossRefPubMed

Lu YM, Chien TM, Li CC, Chou YH, Wu WJ, Huang CN (2018) Urolithiasis is associated with the increased risk for osteoporosis: a nationwide 9-year follow-up study. Urol Sci 29(3):145–150. https://doi.org/10.4103/UROS.UROS_20_17CrossRef

Alexander RT, Hemmelgarn BR, Wiebe N, Bello A, Samuel S, Klarenbach SW, Curhan GC, Tonelli M (2014) Kidney stones and cardiovascular events: a cohort study. Clin J Am Soc Nephrol 9(3):506–512. https://doi.org/10.2215/cjn.04960513CrossRefPubMed

Cheungpasitporn W, Thongprayoon C, Mao MA, O’Corragain OA, Edmonds PJ, Erickson SB (2014) The risk of coronary heart disease in patients with kidney stones: a systematic review and meta-analysis. N Am J Med Sci 6(11):580–585. https://doi.org/10.4103/1947-2714.145477CrossRefPubMedPubMedCentral

10.

Chen Z, Prosperi M, Bird VY (2018) Prevalence of kidney stones in the USA: the national health and nutrition evaluation survey. J Clin Urol. https://doi.org/10.1177/2051415818813820CrossRef

11.

Alelign T, Petros B (2018) Kidney stone disease: an update on current concepts. Adv Urol 2018:3068365. https://doi.org/10.1155/2018/3068365CrossRefPubMedPubMedCentral

12.

Romero V, Akpinar H, Assimos DG (2010) Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol 12(2–3):e86–e96PubMedPubMedCentral

13.

Howden L, Meyer J (2011) Age and Sex Composition:2010 2010 Census Briefs. U.S. Department of Commerce, United States Census Bureau

14.

Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(7):1911–1930. https://doi.org/10.1210/jc.2011-0385CrossRefPubMed

15.

Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC (2003) Time trends in reported prevalence of kidney stones in the United States: 1976–1994. Kidney Int 63(5):1817–1823. https://doi.org/10.1046/j.1523-1755.2003.00917.xCrossRefPubMed

16.

Antonelli JA, Maalouf NM, Pearle MS, Lotan Y (2014) Use of the National Health and Nutrition Examination Survey to calculate the impact of obesity and diabetes on cost and prevalence of urolithiasis in 2030. Eur Urol 66(4):724–729. https://doi.org/10.1016/j.eururo.2014.06.036CrossRefPubMedPubMedCentral

17.

Scales CD Jr, Smith AC, Hanley JM, Saigal CS, Urologic Diseases in America P (2012) Prevalence of kidney stones in the United States. Eur Urol 62(1):160–165. https://doi.org/10.1016/j.eururo.2012.03.052CrossRefPubMedPubMedCentral

18.

Yoon Sung S, Gu Q, Nwankwo T, Wright Jacqueline D, Hong Y, Burt V (2015) Trends in blood pressure among adults with hypertension. Hypertension 65(1):54–61. https://doi.org/10.1161/HYPERTENSIONAHA.114.04012CrossRefPubMed

19.

Hales CM, Fryar CD, Carroll MD, Freedman DS, Ogden CL (2018) Trends in obesity and severe obesity prevalence in US youth and adults by sex and age, 2007-2008 to 2015-2016. JAMA 319(16):1723–1725. https://doi.org/10.1001/jama.2018.3060CrossRefPubMedPubMedCentral

20.

Palmer MK, Toth PP (2019) Trends in lipids, obesity, metabolic syndrome, and diabetes mellitus in the United States: an NHANES analysis (2003-2004 to 2013-2014). Obesity 27(2):309–314. https://doi.org/10.1002/oby.22370CrossRefPubMed

21.

Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK (2019) Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey, 2007–2016. Arthr Rheumatol 71(6):991–999. https://doi.org/10.1002/art.40807CrossRef

22.

Reinstatler L, Khaleel S, Pais VM Jr (2017) Association of pregnancy with stone formation among women in the United States: a NHANES Analysis 2007 to 2012. J Urol 198(2):389–393. https://doi.org/10.1016/j.juro.2017.02.3233CrossRefPubMed

23.

Taylor EN, Curhan GC (2007) Differences in 24-Hour urine composition between black and white women. J Am Soc Nephrol 18(2):654–659. https://doi.org/10.1681/asn.2006080854CrossRefPubMed

24.

Talati JJ, Haroon N, Trinchieri A (2012) Renal stone disease in different racial groups. In: Talati JJ, Tiselius H-G, Albala DM, Ye Z (eds) Urolithiasis: basic science and clinical practice. Springer, London, pp 107–110. https://doi.org/10.1007/978-1-4471-4387-1_14CrossRef

25.

Buckalew VM Jr (1989) Nephrolithiasis in renal tubular acidosis. J Urol 141(3 Pt 2):731–737CrossRefPubMed

26.

Parks JH, Worcester EM, O’Connor RC, Coe FL (2003) Urine stone risk factors in nephrolithiasis patients with and without bowel disease. Kidney Int 63(1):255–265. https://doi.org/10.1046/j.1523-1755.2003.00725.xCrossRefPubMed

27.

Rodman JS, Mahler RJ (2000) Kidney stones as a manifestation of hypercalcemic disorders. Hyperparathyroidism and sarcoidosis. Urol Clin North Am 27(2):275–285CrossRefPubMed

28.

Taylor EN, Stampfer MJ, Curhan GC (2005) Diabetes mellitus and the risk of nephrolithiasis. Kidney Int 68(3):1230–1235. https://doi.org/10.1111/j.1523-1755.2005.00516.xCrossRefPubMed

29.

Taylor EN, Stampfer MJ, Curhan GC (2005) Obesity, weight gain, and the risk of kidney stones. JAMA 293(4):455–462. https://doi.org/10.1001/jama.293.4.455CrossRefPubMed

30.

Curhan GC, Willett WC, Speizer FE, Stampfer MJ (2001) Twenty-four-hour urine chemistries and the risk of kidney stones among women and men. Kidney Int 59(6):2290–2298. https://doi.org/10.1046/j.1523-1755.2001.00746.xCrossRefPubMed

31.

Taylor EN, Curhan GC (2007) Oxalate Intake and the risk for nephrolithiasis. J Am Soc Nephrol 18(7):2198. https://doi.org/10.1681/ASN.2007020219CrossRefPubMed

32.

Mandel EI, Taylor EN, Curhan GC (2013) Dietary and lifestyle factors and medical conditions associated with urinary citrate excretion. Clin J Am Soc Nephrol 8(6):901. https://doi.org/10.2215/CJN.07190712CrossRefPubMedPubMedCentral

33.

Dahlhamer JM, Zammitti EP, Ward BW, Wheaton AG, Croft JB (2016) Prevalence of inflammatory bowel disease among adults aged ≥ 18 years — United States. MMWR Morb Mortal Wkly Rep 65:1166–1169CrossRefPubMed

34.

Rowley WR, Bezold C, Arikan Y, Byrne E, Krohe S (2017) Diabetes 2030: insights from yesterday, today, and future trends. Popul Health Manag 20(1):6–12. https://doi.org/10.1089/pop.2015.0181CrossRefPubMedPubMedCentral

35.

Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ (2015) Prevalence of the metabolic syndrome in the United States, 2003-2012. JAMA 313(19):1973–1974. https://doi.org/10.1001/jama.2015.4260CrossRefPubMed

36.

Yagisawa T, Ito F, Osaka Y, Amano H, Kobayashi C, Toma H (2001) The influence of sex hormones on renal osteopontin expression and urinary constituents in experimental urolithiasis. J Urol 166(3):1078–1082CrossRefPubMed

37.

Soundararajan P, Mahesh R, Ramesh T, Begum VH (2006) Effect of Aerva lanata on calcium oxalate urolithiasis in rats. Indian J Exp Biol 44(12):981–986PubMed

38.

Fan J, Chandhoke PS, Grampsas SA (1999) Role of sex hormones in experimental calcium oxalate nephrolithiasis. J Am Soc Nephrol 10(Suppl 14):S376–S380PubMed

39.

Otunctemur A, Ozbek E, Cakir SS, Dursun M, Polat EC, Ozcan L, Besiroglu H (2015) Urolithiasis is associated with low serum testosterone levels in men. Arch Ital Urol Androl 87(1):83–86. https://doi.org/10.4081/aiua.2015.1.83CrossRefPubMed

40.

Polat EC, Ozcan L, Otunctemur A, Ozbek E (2016) Relation of urinary stone disease with androgenetic alopecia and serum testosterone levels. Urolithiasis 44(5):409–413. https://doi.org/10.1007/s00240-016-0888-3CrossRefPubMed

41.

Wang C, Jackson G, Jones TH, Matsumoto AM, Nehra A, Perelman MA, Swerdloff RS, Traish A, Zitzmann M, Cunningham G (2011) Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care 34(7):1669–1675. https://doi.org/10.2337/dc10-2339CrossRefPubMedPubMedCentral

42.

Tajar A, Forti G, O’Neill TW, Lee DM, Silman AJ, Finn JD, Bartfai G, Boonen S, Casanueva FF, Giwercman A, Han TS, Kula K, Labrie F, Lean ME, Pendleton N, Punab M, Vanderschueren D, Huhtaniemi IT, Wu FC (2010) Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab 95(4):1810–1818. https://doi.org/10.1210/jc.2009-1796CrossRefPubMed

43.

Salam R, Kshetrimayum AS, Keisam R (2012) Testosterone and metabolic syndrome: The link. Indian J Endocrinol Metab 16:S12–S19. https://doi.org/10.4103/2230-8210.94248CrossRefPubMedPubMedCentral

44.

Kohjimoto Y, Sasaki Y, Iguchi M, Matsumura N, Inagaki T, Hara I (2013) Association of metabolic syndrome traits and severity of kidney stones: results from a Nationwide Survey on urolithiasis in Japan. Am J Kidney Dis 61(6):923–929. https://doi.org/10.1053/j.ajkd.2012.12.028CrossRefPubMed

45.

Heller HJ, Sakhaee K, Moe OW, Pak CY (2002) Etiological role of estrogen status in renal stone formation. J Urol 168(5):1923–1927. https://doi.org/10.1097/01.ju.0000033907.21910.beCrossRefPubMed

46.

Zhao Z, Mai Z, Ou L, Duan X, Zeng G (2013) Serum estradiol and testosterone levels in kidney stones disease with and without calcium oxalate components in naturally postmenopausal women. PLoS ONE 8(9):e75513. https://doi.org/10.1371/journal.pone.0075513CrossRefPubMedPubMedCentral

47.

Wilson C (2011) Estrogen and kidney stones. Nat Rev Endocrinol 7(1):3. https://doi.org/10.1038/nrendo.2010.206CrossRefPubMed

48.

Haley WE, Enders FT, Vaughan LE, Mehta RA, Thoman ME, Vrtiska TJ, Krambeck AE, Lieske JC, Rule AD (2016) Kidney function after the first kidney stone event. Mayo Clin Proc 91(12):1744–1752. https://doi.org/10.1016/j.mayocp.2016.08.014CrossRefPubMed

49.

Curhan GC, Taylor EN (2008) 24-h uric acid excretion and the risk of kidney stones. Kidney Int 73(4):489–496. https://doi.org/10.1038/sj.ki.5002708CrossRefPubMed

50.

Taylor EN, Curhan GC (2006) Diet and fluid prescription in stone disease. Kidney Int 70(5):835–839. https://doi.org/10.1038/sj.ki.5001656CrossRefPubMed

51.

Komleh K, Hada P, Pendse AK, Singh PP (1990) Zine, copper and manganese in serum, urine and stones. Int Urol Nephrol 22(2):113–118. https://doi.org/10.1007/BF02549826CrossRefPubMed

52.

Meyer JL, Angino EE (1977) The role of trace metals in calcium urolithiasis. Invest Urol 14(5):347–350PubMed

53.

Ferraro PM, Gambaro G, Curhan GC, Taylor EN (2018) Intake of trace metals and the risk of incident kidney stones. J Urol 199(6):1534–1539. https://doi.org/10.1016/j.juro.2018.01.077CrossRefPubMedPubMedCentral

54.

Johri N, Jaeger P, Ferraro PM, Shavit L, Nair D, Robertson WG, Gambaro G, Unwin RJ (2017) Vitamin D deficiency is prevalent among idiopathic stone formers, but does correction pose any risk? Urolithiasis 45(6):535–543. https://doi.org/10.1007/s00240-016-0954-xCrossRefPubMed

55.

Ferraro PM, Taylor EN, Gambaro G, Curhan GC (2017) Vitamin D intake and the risk of incident kidney stones. J Urol 197(2):405–410. https://doi.org/10.1016/j.juro.2016.08.084CrossRefPubMed

56.

Taylor EN, Hoofnagle AN, Curhan GC (2015) Calcium and phosphorus regulatory hormones and risk of incident symptomatic kidney stones. Clin J Am Soc Nephrol 10(4):667–675. https://doi.org/10.2215/cjn.07060714CrossRefPubMedPubMedCentral

57.

Letavernier E, Daudon M (2018) Vitamin D, hypercalciuria and kidney stones. Nutrients 10(3):366. https://doi.org/10.3390/nu10030366CrossRefPubMedCentral

58.

Tasian GE, Ross ME, Song L, Sas DJ, Keren R, Denburg MR, Chu DI, Copelovitch L, Saigal CS, Furth SL (2016) Annual incidence of nephrolithiasis among children and adults in South Carolina from 1997 to 2012. Clin J Am Soc Nephrol 11(3):488. https://doi.org/10.2215/CJN.07610715CrossRefPubMedPubMedCentral

59.

Kittanamongkolchai W, Vaughan LE, Enders FT, Dhondup T, Mehta RA, Krambeck AE, McCollough CH, Vrtiska TJ, Lieske JC, Rule AD (2018) The changing incidence and presentation of urinary stones over 3 decades. Mayo Clin Proc 93(3):291–299. https://doi.org/10.1016/j.mayocp.2017.11.018CrossRefPubMed

60.

Talati VM, Soares RMO, Khambati A, Nadler RB, Perry KT (2020) Trends in urinary calculi composition from 2005 to 2015: a single tertiary center study. Urolithiasis 48(4):305–311. https://doi.org/10.1007/s00240-019-01151-zCrossRefPubMed

Title: Trends in the prevalence of kidney stones in the United States from 2007 to 2016
Authors: Api Chewcharat
Gary Curhan
Publication date: 01-02-2021
Publisher: Springer Berlin Heidelberg
Keywords: Gout
Testosterone
Published in: Urolithiasis / Issue 1/2021
Print ISSN: 2194-7228
Electronic ISSN: 2194-7236
DOI: https://doi.org/10.1007/s00240-020-01210-w

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Trends in the prevalence of kidney stones in the United States from 2007 to 2016

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Gender-related differences in the performance of sequential organ failure assessment (SOFA) to predict septic shock after percutaneous nephrolithotomy

Characteristics of the genotype and phenotype in Chinese primary hyperoxaluria type 1 populations

Correction to: Is health‑related quality of life of patients after single‑use flexible ureteroscopy superior to extracorporeal shock wave lithotripsy? A randomised prospective study

Surface analysis of ureteral stent before and after implantation in the bodies of child patients

Does the renal parenchymal thickness affect the efficacy of the retrograde intrarenal surgery? A prospective cohort study

Differentiation of distal ureteral stones and pelvic phleboliths using a convolutional neural network